|
Volumn 23, Issue 5, 2015, Pages 1027-1043
|
Synthesis and structure-activity relationships of novel phenoxyacetamide inhibitors of the Pseudomonas aeruginosa type III secretion system (T3SS)
|
Author keywords
Mitsunobu reaction; Phenoxyacetamide; Pseudomonas aeruginosa; Type III secretion system; Virulence factor
|
Indexed keywords
1 METHYLINDOLE 5 YLBENZYLAMINE;
2 CHLOROPHENYLBENZYLAMINE;
2 FLUOROPHENYLBENZYLAMINE;
2 METHOXYPHENYLBENZYLAMINE;
2 METHYLPHENYLBENZYLAMINE;
2,4 DIMETHOXYPHENYLBENZYLAMINE;
3 CHLOROPHENYLBENZYLAMINE;
3 FLUOROPHENYLBENZYLAMINE;
3 METHOXYPHENYLBENZYLAMINE;
3 METHYLPHENYLBENZYLAMINE;
3,4 DIMETHOXYPHENYLBENZYLAMINE;
3,4 METHYLENEDIOXYPHENYLBENZYLAMINE;
4 CHLOROPHENYLBENZYLAMINE;
4 FLUOROPHENYLBENZYLAMINE;
4 METHOXYPHENYLBENZYLAMINE;
4 METHYLPHENYLBENZYLAMINE;
ACETAMIDE DERIVATIVE;
ANTIBIOTIC AGENT;
BENZIMIDAZOLE 5 YLBENZYLAMINE;
BENZOFURAN 5 YLBENZYLAMINE;
BENZOTHIOPHENE 5 YLBENZYLAMINE;
INDOLE 2 YLBENZYLAMINE;
INDOLE 4 YLBENZYLAMINE;
INDOLE 5 YLBENZYLAMINE;
INDOLE 6 YLBENZYLAMINE;
PHENOXYACETAMIDE;
PHENOXYACETAMIDE INHIBITOR DERIVATIVE;
PHENYLBENZYLAMINE;
PYRROLO[2,3 B]PYRIDIN 5 YLBENZYLAMINE;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
ACETIC ACID DERIVATIVE;
AMIDE;
ANTIINFECTIVE AGENT;
PHENOXYACETIC ACID;
ANTIBACTERIAL ACTIVITY;
ANTIBIOTIC RESISTANCE;
ANTIBIOTIC SENSITIVITY;
ARTICLE;
CONTROLLED STUDY;
DRUG CYTOTOXICITY;
DRUG POTENCY;
DRUG RESPONSE;
DRUG SCREENING;
DRUG STRUCTURE;
DRUG SYNTHESIS;
DRUG TARGETING;
HIGH THROUGHPUT SCREENING;
IC50;
MINIMUM INHIBITORY CONCENTRATION;
NONHUMAN;
PSEUDOMONAS AERUGINOSA;
STRUCTURE ACTIVITY RELATION;
TYPE III SECRETION SYSTEM;
ANIMAL;
CHEMISTRY;
CHO CELL LINE;
CRICETULUS;
DRUG EFFECTS;
HAMSTER;
METABOLISM;
BACTERIA (MICROORGANISMS);
PSEUDOMONAS AERUGINOSA;
ACETATES;
AMIDES;
ANIMALS;
ANTI-BACTERIAL AGENTS;
CHO CELLS;
CRICETINAE;
CRICETULUS;
PSEUDOMONAS AERUGINOSA;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
EID: 84923090939
PISSN: 09680896
EISSN: 14643391
Source Type: Journal
DOI: 10.1016/j.bmc.2015.01.011 Document Type: Article |
Times cited : (33)
|
References (33)
|